NSE · DIVISLAB

Divi's Laboratories share price, financials and monitoring

Divi's Laboratories manufactures pharmaceutical ingredients and provides custom synthesis. Customer programmes, product mix, utilisation and capital expenditure influence its results.

HealthcarePharmaceuticals & BiotechnologyCorporatePage reviewed 5 Nov 2026
Last NSE close₹10,037.5Bhavcopy · 4 Nov 2026 · end of day
Market cap₹2,65,994 crCalculated on 4 Nov 2026
P/E91.1×TTM EPS through 30 Jun 2026
P/B15.9×As of 4 Nov 2026

Dates and sources

The last NSE bhavcopy close is dated 4 Nov 2026. Valuation observations are dated 4 Nov 2026. The latest financial quarter ends 30 Jun 2026. These are separate observation dates, not live quotes. Financial reporting basis: consolidated.

Read the Nifty drivers report · Understand index funds and ETFs · NSE daily reports

Latest reported evidence

Year ended 2026-03-31 and the latest quarter

The tables use one reporting basis across the displayed history, preferring consolidated where sufficient history is available. Each row identifies its period and original filing. Profit is attributable to owners where disclosed; otherwise total profit is labelled.

Year ended 2026-03-31 Revenue₹10,560 crYear ended 31 Mar 2026
Year ended 2026-03-31 PAT₹2,568 crAttributable to owners · 31 Mar 2026
Latest-quarter PAT₹902 crQuarter ended 30 Jun 2026
ROCE21.5%Ratio observation: 31 Mar 2026
Annual observations

Revenue history

A rising top line is evidence of scale, not proof of value creation. Read it with profit, capital efficiency, cash conversion and the business-specific guideposts above.

How to read these figures

₹ crore values are presented as filed or normalized from company/exchange financial results. Banks and NBFCs use total income because interest is part of their operating business. Industrial companies use revenue where available.

Historical values can be restated. EPS retains the share basis in its original filing and may not be directly comparable across corporate actions. Gaps in annual periods remain gaps; the source and reporting basis are retained.

Year endedRevenuePATReported EPSBasisEvidence
Year ended 2022-03-3131 Mar 2022₹8,960 cr₹2,960 cr111.52Consolidated · PAT: ownersFiling ↗
Year ended 2023-03-3131 Mar 2023₹7,768 cr₹1,823 cr68.69Consolidated · PAT: ownersFiling ↗
Year ended 2024-03-3131 Mar 2024₹7,845 cr₹1,600 cr60.27Consolidated · PAT: ownersFiling ↗
Year ended 2025-03-3131 Mar 2025₹9,360 cr₹2,191 cr82.53Consolidated · PAT: ownersFiling ↗
Year ended 2026-03-3131 Mar 2026₹10,560 cr₹2,568 cr96.75Consolidated · PAT: ownersFiling ↗
Quarterly results

Eight reported quarters

Publication date is shown separately from the period end. A June quarter was not knowable on 30 June; it entered the public record only when the company filed it.

Quarter endedRevenuePATReported EPSPublishedEvidence
30 Jun 2026Consolidated · PAT: owners₹3,080 cr₹902 cr33.951 Aug 2026Filing ↗
31 Mar 2026Consolidated · PAT: owners₹2,831 cr₹751 cr28.3123 May 2026Filing ↗
31 Dec 2025Consolidated · PAT: owners₹2,604 cr₹583 cr21.9811 Feb 2026Filing ↗
30 Sept 2025Consolidated · PAT: owners₹2,715 cr₹689 cr25.977 Nov 2025Filing ↗
30 Jun 2025Consolidated · PAT: owners₹2,410 cr₹545 cr20.496 Aug 2025Filing ↗
31 Mar 2025Consolidated · PAT: owners₹2,585 cr₹662 cr24.9317 May 2025Filing ↗
31 Dec 2024Consolidated · PAT: owners₹2,319 cr₹589 cr22.23 Feb 2025Filing ↗
30 Sept 2024Consolidated · PAT: owners₹2,338 cr₹510 cr19.29 Nov 2024Filing ↗
Returns and profitability

Use the metric that fits the business.

ROCE is not shown for banks and NBFCs because deposits and borrowings are operating raw material rather than ordinary financing. Missing or inapplicable values remain unavailable.

ROCE21.5%Period ended 31 Mar 2026
ROE16.2%Period ended 31 Mar 2026
ROA13.9%Period ended 31 Mar 2026
Net profit margin25.0%TTM through 30 Jun 2026
EBIT margin33.1%TTM through 30 Jun 2026
Profit growth26.8%YoY through 30 Jun 2026
Ownership

Who owns the company?

Shareholding is shown from the latest available filing. Institutional subtotals depend on the filing taxonomy and are labelled by their source basis.

Latest ownership period30 Sept 2026
Institution basisFiled institutional subtotal
Promoter and group51.9%Filed for 30 Sept 2026
FII holding20.4%+0.18 pp QoQ
DII holding19.2%-0.21 pp QoQ
Forensic context

Profit is only one part of the evidence.

These are investigation prompts, not pass-or-fail verdicts. Business model, working-capital structure and reporting basis determine how each value should be interpreted.

Cash conversion0.8×CFO divided by TTM PAT
CFO to PAT1.1×FY ended 31 Mar 2026
Accruals ratio-0.9%Lower is generally cleaner, but context matters
Borrowings₹0 crFY ended 31 Mar 2026
Observation scope

Dated evidence, linked to its source.

The page shows selected annual and quarterly periods. The financial tables, market observations and ownership figures can have different dates.

Displayed annual history31 Mar 2022 to 31 Mar 2026
Latest financial quarter30 Jun 2026
NSE closing price4 Nov 2026
Page reviewed5 Nov 2026
Questions investors ask

Divi's Laboratories FAQ

What does Divi's Laboratories do?

Divi's Laboratories manufactures pharmaceutical ingredients and provides custom synthesis. Customer programmes, product mix, utilisation and capital expenditure influence its results.

What should investors monitor for Divi's Laboratories?

Important operating evidence includes custom synthesis mix, capacity utilisation, research programmes, capital expenditure. These are research guideposts, not automatic trading signals.

Are the Divi's Laboratories financials consolidated or standalone?

Altys prefers consolidated financials when available and labels the reporting basis in each table. The latest annual row on this page is consolidated.

Does Altys recommend buying or selling Divi's Laboratories?

No. Altys provides sourced financial data, research context and monitoring infrastructure. It does not issue a buy, sell or hold recommendation on this page.

Continuous research

Research Divi's Laboratories once. Keep watching what changes.

Altys can connect new results, filings, concalls, guidance, ownership and company-specific KPIs with the investment team’s original thesis and portfolio context.